568a845e-d8a0-47b5-af77-896831524b16
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.450
- E2F_TARGETS+0.440
- IL6_JAK_STAT3_SIGNALING+0.430
- G2M_CHECKPOINT+0.410
- MYC_TARGETS_V1+0.330
- TNFA_SIGNALING_VIA_NFKB+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.320
- PI3K_AKT_MTOR_SIGNALING+0.250
- ALLOGRAFT_REJECTION+0.240
- MTORC1_SIGNALING+0.220
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- MYOGENESIS-0.320
- APICAL_SURFACE-0.300
- APICAL_JUNCTION-0.270
- OXIDATIVE_PHOSPHORYLATION-0.230
- FATTY_ACID_METABOLISM-0.200
- CHOLESTEROL_HOMEOSTASIS-0.190
- UV_RESPONSE_DN-0.170
- COAGULATION-0.160
- HEDGEHOG_SIGNALING-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1XK-01A-21R-A14M-07 | — | E | 0.840 |
| 2 | TCGA-C8-A27B-01A-11R-A169-07 | — | E | 0.799 |
| 3 | 2afaf830-457d-42d1-8697-e5c9a2d885a1 | — | — | 0.773 |
| 4 | SRR1313135 | — | C | 0.762 |
| 5 | SRR12475159 | — | — | 0.761 |
| 6 | TCGA-BH-A209-01A-11R-A157-07 | — | D | 0.748 |
| 7 | TCGA-A2-A0CM-01A-31R-A034-07 | — | E | 0.744 |
| 8 | SRR8518156 | — | D | 0.741 |
| 9 | MNG988 | — | — | 0.739 |
| 10 | 83a1d91a-3e74-4106-96d1-eec558404c29 | — | — | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |